Explore 3 Stock Ideas & Industry Insights Download Free Report

bioMérieux S.A

Healthcare US BMXMF

83.31USD
0.00(0%)

Last update at 2026-06-03T20:00:00Z

Day Range

82.0084.00
LowHigh

52 Week Range

102.25152.00
LowHigh

Fundamentals

  • Previous Close 83.31
  • Market Cap13952.14M
  • Volume158
  • P/E Ratio29.26
  • Dividend Yield0.93%
  • EBITDA1129.70M
  • Revenue TTM4069.80M
  • Revenue Per Share TTM34.49
  • Gross Profit TTM 2308.80M
  • Diluted EPS TTM3.93

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 525.30M 579.30M 437.40M 580.50M 774.30M
Minority interest 0.60M 7.10M 34.80M 11.80M 2.90M
Net income 397.35M 432.20M 357.60M 452.40M 601.10M
Selling general administrative 1111.20M 313.80M 295.00M 253.20M 242.60M
Selling and marketing expenses - 783.80M 725.50M 701.50M 575.70M
Gross profit 2141.20M 2215.30M 2057.30M 2008.60M 1963.70M
Reconciled depreciation 438.40M 325.20M 388.50M 277.00M 231.00M
Ebit 560.99M 595.30M 569.00M 665.60M 802.90M
Ebitda 999.23M 897.50M 857.80M 942.60M 1033.90M
Depreciation and amortization 438.24M 302.20M 288.80M 277.00M 231.00M
Non operating income net other - - - - -
Operating income 560.99M 588.80M 439.00M 587.20M 784.30M
Other operating expenses 3507.29M 3391.10M 3235.70M 2925.30M 2575.20M
Interest expense 15.80M 16.56M 4.40M 4.10M 9.10M
Tax provision 128.80M 154.30M 114.50M 140.10M 175.60M
Interest income 13.20M 0.50M 1.40M 1.20M 1.70M
Net interest income 4.30M -9.40000M -1.70000M -5.20000M -9.80000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 128.75M 154.30M 114.50M 140.10M 175.60M
Total revenue 4068.28M 3979.90M 3674.70M 3589.00M 3376.20M
Total operating expenses 1580.21M 1626.50M 1618.30M 1344.90M 1162.70M
Cost of revenue 1927.08M 1764.60M 1617.40M 1580.40M 1412.50M
Total other income expense net -35.68663M -9.50000M -1.60000M -6.70000M -10.00000M
Discontinued operations - - - - -
Net income from continuing ops 396.80M 425.10M 322.90M 440.40M 598.00M
Net income applicable to common shares - - - 452.40M 601.10M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5572.61M 5770.00M 5259.20M 5186.60M 4616.80M
Intangible assets 401.35M 492.00M 528.60M 625.00M 411.50M
Earning assets - - - - -
Other current assets - 156.40M 215.70M 38.80M 43.70M
Total liab 1468.15M 1559.00M 1507.00M 1543.70M 1442.20M
Total stockholder equity 4100.56M 4204.90M 3752.20M 3604.20M 3123.20M
Deferred long term liab - - - - -
Other current liab 670.95M 686.10M 606.00M 122.50M 95.90M
Common stock 12.00M 12.00M 12.00M 12.00M 12.00M
Capital stock 12.00M 12.00M 12.00M 12.00M 12.00M
Retained earnings 397.50M 432.20M 357.60M 452.40M 601.10M
Other liab - - - 94.20M 123.70M
Good will 727.53M 730.40M 698.80M 812.50M 669.50M
Other assets - -0.10000M 0.10M 0.10M 0.10M
Cash 569.59M 449.80M 352.40M 552.60M 803.50M
Cash and equivalents - - - - -
Total current liabilities 1064.30M 1134.90M 1087.30M 1131.10M 955.90M
Current deferred revenue - - 52.80M 552.20M 520.80M
Net debt -108.35940M 40.90M 166.40M -47.20000M -341.00000M
Short term debt 131.35M 141.00M 163.40M 187.00M 99.70M
Short long term debt 99.30M 111.60M 136.10M 160.80M 99.70M
Short long term debt total 461.23M 490.70M 518.80M 505.40M 462.50M
Other stockholder equity 4088.57M 3760.70M 3401.10M 3139.80M 2510.10M
Property plant equipment - - - 1369.90M 1224.80M
Total current assets 2539.45M 2501.10M 2205.20M 2216.60M 2207.10M
Long term investments - - - - -
Net tangible assets - - - 2166.70M 2042.10M
Short term investments - - 14.20M -19.80000M -27.50000M
Net receivables 1010.52M 857.60M 728.60M 740.10M 701.40M
Long term debt 211.30M 207.10M 234.10M 224.80M 362.80M
Inventory 959.34M 1037.30M 908.50M 737.20M 634.60M
Accounts payable 262.00M 272.40M 265.10M 269.40M 239.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -18.50000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 10.30M 24.80M 114.60M 12.80M 12.50M
Deferred long term asset charges - - - - -
Non current assets total 3033.16M 3268.90M 3054.00M 2969.90M 2409.60M
Capital lease obligations 150.80M 172.00M 148.60M 119.90M 122.40M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -1.00000M -359.80000M -488.80000M -528.10000M -0.40000M
Change to liabilities - - - 9.90M 24.20M
Total cashflows from investing activities -461.52708M -359.80000M -488.80000M -528.10000M -307.30000M
Net borrowings -29.60000M -74.80000M -34.80000M 14.30M -50.10000M
Total cash from financing activities -155.34180M -212.60000M -122.30000M -244.20000M -127.00000M
Change to operating activities - - - 71.90M -21.80000M
Net income 397.35M 425.10M 322.80M 440.50M 598.20M
Change in cash 173.28M 108.70M -195.30000M -258.60000M 416.00M
Begin period cash flow 396.31M 333.40M 528.70M 787.30M 371.30M
End period cash flow 569.59M 442.10M 333.40M 528.70M 787.30M
Total cash from operating activities 788.00M 667.30M 445.40M 475.10M 811.10M
Issuance of capital stock - - - 0.00000M 0.00000M
Depreciation 438.24M 325.20M 258.90M 277.00M 231.00M
Other cashflows from investing activities -0.09996M 0.60M -0.00000M - -
Dividends paid 106.06M 100.20M 100.20M -101.20000M -73.10000M
Change to inventory -10.09622M -85.10000M -192.60000M -92.10000M -62.40000M
Change to account receivables -28.98914M -53.70000M -13.70000M -145.60000M 23.60M
Sale purchase of stock -18.19318M -37.60000M - -157.20000M -3.80000M
Other cashflows from financing activities -1.49944M - 12.70M -0.10000M 18.20M
Change to netincome - - - -98.40000M -1.40000M
Capital expenditures 335.17M 345.80M 338.30M 286.70M 290.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -71.27330M -51.00000M -206.70000M -155.90000M -36.40000M
Stock based compensation 26.50M 23.40M 19.70M 13.00M 12.40M
Other non cash items 23.69M -55.40000M 50.70M -3.60000M 24.00M
Free cash flow 452.83M 321.50M 107.10M 188.40M 521.00M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BMXMF
bioMérieux S.A
- -% 83.31 29.26 19.27 3.43 2.58 2.59 12.40
TMO
Thermo Fisher Scientific Inc
8.08 1.70% 482.03 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
8.56 4.81% 186.64 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc
0.97 0.71% 138.37 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc
4.01 0.72% 564.74 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

Profile

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.

bioMérieux S.A

376 Chemin De l?Orme, Marcy-l'Étoile, France, 69280

Key Executives

Name Title Year Born
Mr. Alexandre Merieux Chairman & CEO 1974
Mr. Pierre Boulud Chief Operating Officer of Clinical Operations 1971
Mr. Frederic Beseme Head of CSR 1956
Mr. Guillaume Bouhours Exec. VP of Purchasing and Information Systems & CFO 1976
Sylvain Morgeau Investor Relations NA
Ms. Valerie Leylde Exec. VP of HR, Communications & CSR NA
Mr. François Lacoste Exec. VP of R&D NA
Mr. Mark Miller Exec. VP of Medical Affairs NA
Mr. Pierre Charbonnier Exec. VP of Quality, Manufacturing & Supply Chain NA
Mr. Yasha Mitrotti Exec. VP of Industrial Microbiology NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions